With New York being at the crossroads of the HIV epidemic and the coronavirus disease 2019 (COVID-19) pandemic, a group of researchers wanted to know what, if any, correlation there was between the 2 disease states.
Persons living with HIV may be predisposed to more severe coronavirus disease 2019 (COVID-19) infection compared with those who do not have HIV, reports a study published in JAMA Network Open. Higher rates of hospitalization and death are also likely.
“Persons living with diagnosed HIV infection with a low CD4 cell count or not receiving HIV treatment are currently listed by the [CDC] as possibly at risk for severe illness from COVID-19,” the study authors noted, but just how much that risk is elevated and the actual rates of serious COVID-19–related outcomes remain unknown.
With New York being at the crossroads of the HIV epidemic and the COVID-19 pandemic, a group of researchers wanted to know what, if any, correlation there was between the 2 disease states. “Is there an association between prior diagnosis of HIV infection and [COVID-19] diagnosis, hospitalization, and in-hospital death among residents of New York state?” they asked.
Their retrospective cohort analysis found an overall 6.9% (n = 207) in-hospital mortality rate among all persons living with HIV who were hospitalized (n = 896) through June 15 because of severe cases of COVID-19. This represents elevated rates per population (standardized rate ratio [sRR], 1.23; 95% CI, 1.07-1.40) and among diagnosed individuals (sRR, 1.30; 95% CI, 1.13-1.48). However, it does not mark a mortality jump among those hospitalized (sRR, 0.96; 95% CI, 0.83-1.09).
In addition, after standardization, despite overall similar COVID-19 diagnosis rates vs persons not living with HIV (sRR, 0.94; 95% CI, 0.91-0.97), the investigators saw higher levels of the following among the HIV cohort:
Risk of hospitalization remained elevated among the 3 HIV stages when the investigators looked at this outcome relative to persons without diagnosed HIV:
Unadjusted analysis also uncovered the following among individuals living with HIV:
Compared with the same time period in 2019, which saw 490 HIV-related deaths, the 207 COVID-19–related study deaths “represent a 42% addition to anticipated deaths during this same interval in 2020,” the authors noted.
Both the city and the state were included in this cohort study of 2998 patients living with HIV (70.6% men; 80.6% in New York City; mean [SD] age, 54.0 [13.3] years) and diagnosed COVID-19 (2.8% of all persons with diagnosed HIV in the state), which took place between March 1 and June 15, 2020. The investigation incorporated HIV surveillance data from the state HIV surveillance registry, COVID-19 laboratory-confirmed diagnoses data from New York’s Electronic Clinical Laboratory Reporting System, and hospitalization data from the State Health Information Network for NY, with the goal to uncover trends in COVID-19 diagnosis, hospitalization, and in-hospital mortality.
“Because HIV infection is a marker for, and may play a direct role in, more severe COVID-19 outcomes, persons living with diagnosed HIV (with any CD4 count) may warrant recategorization from ‘might be at increased risk’ to ‘increased risk’ in the [CDC]’s underlying medical conditions list,” the authors conclude. “Our findings present an opportunity to address health equity with regard to HIV and COVID-19 through a combination of prevention and treatment approaches.”
Reference
Tesoriero JM, Swain CAE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open. Published online February 3, 2021. doi:10.1001/jamanetworkopen.2020.37069
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More